Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

WAKIX generated $269 million in net revenue in Q3, with 400 net patient adds during the quarter. The company reiterated full-year guidance of $1.0 billion to $1.04 billion; the headline cites strong demand but provides no comparison with prior results or expectations.